Target Markets Position MBF Therapeutics' DNA vaccine platform as a solution for swine health agencies and veterinary distributors focusing on Porcine Reproductive and Respiratory Syndrome (PRRS) and African Swine Fever (ASF) prevention to reduce economic losses in global pig production.

Strategic Partnerships Leverage current collaborations and breadth of expertise to pursue co-development or licensing deals with large animal health players, academic labs, and translational partners aiming to accelerate development and commercialization of universal cross-protective vaccines.

Safety and Efficacy Highlight the platform’s safety benefits over traditional killed or live vaccines, and emphasize durable T cell–mediated immunity to appeal to customers seeking more effective, herd-safe vaccination solutions for respiratory viral diseases.

Early Commercial Readiness With existing revenue and a demonstrated focus on veterinary applications, target early adopters in swine production, feed companies, and veterinary distributors who value innovative DNA-based immunotherapies for rapid differentiation.

Global market Risk Capitalize on the expanding risk of ASF outbreaks and market disruption to create urgency in purchasing MBF’s platform-based vaccines, offering scalable development timelines and shared risk through partnerships or milestone-driven contracts.